PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors targeting Programmed cell Death protein 1 (PD‐1) and Programmed Death‐Ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC).